Pregabalin

Chemical formula: C₈H₁₇NO₂  Molecular mass: 159.226 g/mol  PubChem compound: 5486971

Interactions

Pregabalin interacts in the following cases:

Opioids

Caution is advised when prescribing pregabalin concomitantly with opioids due to risk of CNS depression. In a case-control study of opioid users, those patients who took pregabalin concomitantly with an opioid had an increased risk for opioid-related death compared to opioid use alone (adjusted odds ratio [aOR], 1.68 [95% CI, 1.19–2.36]). This increased risk was observed at low doses of pregabalin (≤300 mg, aOR 1.52 [95% CI, 1.04–2.22]) and there was a trend for a greater risk at high doses of pregabalin (>300 mg, aOR 2.51 [95% CI 1.24–5.06]).

Reduced lower gastrointestinal tract function

There are postmarketing reports of events related to reduced lower gastrointestinal tract function (e.g. intestinal obstruction, paralytic ileus, constipation) when pregabalin was co-administered with medications that have the potential to produce constipation, such as opioid analgesics. When pregabalin and opioids will be used in combination, measures to prevent constipation may be considered (especially in female patients and elderly).

Renal impairment

Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug.

As pregabalin clearance is directly proportional to creatinine clearance, dose reduction in patients with compromised renal function must be individualised according to creatinine clearance (CLcr), as indicated in Table 1 determined using the following formula:

CLcr = [1.23 X [140 - age (years)] X weight (kg) / serum creatinine (μmol/l)] (X 0.85 for female patients)

Pregabalin is removed effectively from plasma by haemodialysis (50% of drug in 4 hours). For patients receiving haemodialysis, the pregabalin daily dose should be adjusted based on renal function. In addition to the daily dose, a supplementary dose should be given immediately following every 4 hour haemodialysis treatment (see Table 1).

Table 1. Pregabalin Dose Adjustment Based on Renal Function:

Creatinine
clearance
(CLcr)
(ml/min)
Total pregabalin daily dose*Dose regimen
 Starting dose
(mg/day)
Maximum dose
(mg/day)
 
≥60150600BID or TID
≥30 - <6075300BID or TID
≥15 - <3025–50150Once Daily or BID
<152575Once Daily
Supplementary dosage following haemodialysis (mg)
 25100Single dose+

TID = Three divided doses
BID = Two divided doses
* Total daily dose (mg/day) should be divided as indicated by dose regimen to provide mg/dose
+ Supplementary dose is a single additional dose

Central nervous system influencing medical products

Pregabalin may potentiate the effects of ethanol and lorazepam.

In the postmarketing experience, there are reports of respiratory failure, coma and deaths in patients taking pregabalin and opioids and/or other central nervous system (CNS) depressant medicinal products. Pregabalin appears to be additive in the impairment of cognitive and gross motor function caused by oxycodone.

Fertility

There are no clinical data on the effects of pregabalin on female fertility.

In a clinical trial to assess the effect of pregabalin on sperm motility, healthy male subjects were exposed to pregabalin at a dose of 600 mg/day. After 3 months of treatment, there were no effects on sperm motility.

A fertility study in female rats has shown adverse reproductive effects. Fertility studies in male rats have shown adverse reproductive and developmental effects. The clinical relevance of these findings is unknown.

History of substance abuse

Pregabalin can cause drug dependence, which may occur at therapeutic doses. Cases of abuse and misuse have been reported. Patients with a history of substance abuse may be at higher risk for pregabalin misuse, abuse and dependence, and pregabalin should be used with caution in such patients. Before prescribing pregabalin, the patient's risk of misuse, abuse or dependence should be carefully evaluated.

Congestive heart failure

There have been postmarketing reports of congestive heart failure in some patients receiving pregabalin. These reactions are mostly seen in elderly cardiovascular compromised patients during pregabalin treatment for a neuropathic indication. Pregabalin should be used with caution in these patients. Discontinuation of pregabalin may resolve the reaction.

Diabetes mellitus

In accordance with current clinical practice, some diabetic patients who gain weight on pregabalin treatment may need to adjust hypoglycaemic medicinal products.

Pregnancy

Studies in animals have shown reproductive toxicity.

Pregabalin has been shown to cross the placenta in rats. Pregabalin may cross the human placenta.

Major congenital malformations

Data from a Nordic observational study of more than 2700 pregnancies exposed to pregabalin in the first trimester showed a higher prevalence of major congenital malformations (MCM) among the paediatric population (live or stillborn) exposed to pregabalin compared to the unexposed population (5.9% vs. 4.1%).

The risk of MCM among the paediatric population exposed to pregabalin in the first trimester was slightly higher compared to unexposed population (adjusted prevalence ratio and 95% confidence interval: 1.14 (0.96-1.35)), and compared to population exposed to lamotrigine (1.29 (1.01–1.65)) or to duloxetine (1.39 (1.07–1.82)).

The analyses on specific malformations showed higher risks for malformations of the nervous system, the eye, orofacial clefts, urinary malformations and genital malformations, but numbers were small and estimates imprecise.

Pregabalin should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the foetus).

Nursing mothers

Pregabalin is excreted into human milk. The effect of pregabalin on newborns/infants is unknown. A decision must be made whether to discontinue breast-feeding or to discontinue pregabalin therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Carcinogenesis, mutagenesis and fertility

Women of childbearing potential/Contraception

Women of childbearing potential have to use effective contraception during treatment.

Fertility

There are no clinical data on the effects of pregabalin on female fertility.

In a clinical trial to assess the effect of pregabalin on sperm motility, healthy male subjects were exposed to pregabalin at a dose of 600 mg/day. After 3 months of treatment, there were no effects on sperm motility.

A fertility study in female rats has shown adverse reproductive effects. Fertility studies in male rats have shown adverse reproductive and developmental effects. The clinical relevance of these findings is unknown.

Effects on ability to drive and use machines

Pregabalin may have minor or moderate influence on the ability to drive and use machines. Pregabalin may cause dizziness and somnolence and therefore may influence the ability to drive or use machines. Patients are advised not to drive, operate complex machinery or engage in other potentially hazardous activities until it is known whether this medicinal product affects their ability to perform these activities.

Adverse reactions


The pregabalin clinical programme involved over 8,900 patients exposed to pregabalin, of whom over 5,600 were in double-blind placebo controlled trials. The most commonly reported adverse reactions were dizziness and somnolence. Adverse reactions were usually mild to moderate in intensity. In all controlled studies, the discontinuation rate due to adverse reactions was 12% for patients receiving pregabalin and 5% for patients receiving placebo. The most common adverse reactions resulting in discontinuation from pregabalin treatment groups were dizziness and somnolence.

In the table below all adverse reactions, which occurred at an incidence greater than placebo and in more than one patient, are listed by class and frequency (very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

The adverse reactions listed may also be associated with the underlying disease and/or concomitant medicinal products.

In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse reactions in general, CNS adverse reactions and especially somnolence was increased.

Additional reactions reported from postmarketing experience are included in italics in the list below.

Pregabalin Adverse Drug Reactions:

System Organ ClassAdverse drug reactions
Infections and infestations
CommonNasopharyngitis
Blood and lymphatic system disorders
UncommonNeutropaenia
Immune system disorders
UncommonHypersensitivity
RareAngioedema, allergic reaction
Metabolism and nutrition disorders
CommonAppetite increased
UncommonAnorexia, hypoglycaemia
Psychiatric disorders
CommonEuphoric mood, confusion, irritability, disorientation, insomnia,libido decreased
UncommonHallucination, panic attack, restlessness, agitation, depression,
depressed mood, elevated mood, aggression, mood swings,
depersonalisation, word finding difficulty, abnormal dreams, libido
increased, anorgasmia, apathy
RareDisinhibition, suicidal behaviour, suicidal ideation
Not knownDrug dependence
Nervous system disorders
Very CommonDizziness, somnolence, headache
CommonAtaxia, coordination abnormal, tremor, dysarthria, amnesia,
memory impairment, disturbance in attention, paraesthesia,
hypoaesthesia, sedation, balance disorder, lethargy
UncommonSyncope, stupor, myoclonus, loss of consciousness, psychomotor
hyperactivity, dyskinesia, dizziness postural, intention tremor,
nystagmus, cognitive disorder, mental impairment, speech disorder,
hyporeflexia, hyperaesthesia, burning sensation, ageusia, malaise
RareConvulsions, parosmia, hypokinesia, dysgraphia, parkinsonism
Eye disorders
CommonVision blurred, diplopia
UncommonPeripheral vision loss, visual disturbance, eye swelling, visual field
defect, visual acuity reduced, eye pain, asthenopia, photopsia, dry
eye, lacrimation increased, eye irritation
RareVision loss, keratitis, oscillopsia, altered visual depth perception,
mydriasis, strabismus, visual brightness
Ear and labyrinth disorders
CommonVertigo
UncommonHyperacusis
Cardiac disorders
UncommonTachycardia, atrioventricular block first degree, sinus bradycardia,
congestive heart failure
RareQT prolongation, sinus tachycardia, sinus arrhythmia
Vascular disorders
UncommonHypotension, hypertension, hot flushes, flushing, peripheral
coldness
Respiratory, thoracic and mediastinal disorders
UncommonDyspnoea, epistaxis, cough, nasal congestion, rhinitis, snoring,
nasal dryness
RarePulmonary oedema, throat tightness
Not knownRespiratory depression
Gastrointestinal disorders
CommonVomiting, nausea, constipation, diarrhoea, flatulence, abdominal
distension, dry mouth
UncommonGastrooesophageal reflux disease, salivary hypersecretion,
hypoaesthesia oral
RareAscites, pancreatitis, swollen tongue, dysphagia
Hepatobiliary disorders
UncommonElevated liver enzymes*
RareJaundice
Very rareHepatic failure, hepatitis
Skin and subcutaneous tissue disorders
UncommonRash papular, urticaria, hyperhidrosis, pruritus
RareToxic epidermal necrolysis, Stevens-Johnson syndrome, cold sweat
Musculoskeletal and connective tissue disorders
CommonMuscle cramp, arthralgia, back pain, pain in limb, cervical spasm
UncommonJoint swelling, myalgia, muscle twitching, neck pain, muscle
stiffness
RareRhabdomyolysis
Renal and urinary disorders
UncommonUrinary incontinence, dysuria
RareRenal failure, oliguria, urinary retention
Reproductive system and breast disorders
CommonErectile dysfunction
UncommonSexual dysfunction, ejaculation delayed, dysmenorrhoea, breast
pain
RareAmenorrhoea, breast discharge, breast enlargement, gynaecomastia
General disorders and administration site conditions
CommonOedema peripheral, oedema, gait abnormal, fall, feeling drunk,
feeling abnormal, fatigue
UncommonGeneralised oedema, face oedema, chest tightness, pain, pyrexia,
thirst, chills, asthenia
Investigations
CommonWeight increased
UncommonBlood creatine phosphokinase increased, blood glucose increased,
platelet count decreased, blood creatinine increased, blood
potassium decreased, weight decreased
RareWhite blood cell count decreased

* Alanine aminotransferase increased (ALT) and aspartate aminotransferase increased (AST).

After discontinuation of short-term and long-term treatment with pregabalin withdrawal symptoms have been observed. The following symptoms have been reported: insomnia, headache, nausea, anxiety, diarrhoea, flu syndrome, convulsions, nervousness, depression, suicidal ideation, pain, hyperhidrosis and dizziness. These symptoms may indicate drug dependence. The patient should be informed about this at the start of the treatment. Concerning discontinuation of long-term treatment of pregabalin, data suggest that the incidence and severity of withdrawal symptoms may be dose-related.

Paediatric population

The pregabalin safety profile observed in five paediatric studies in patients with partial seizures with or without secondary generalisation (12-week efficacy and safety study in patients 4 to 16 years of age, n=295; 14-day efficacy and safety study in patients 1 month to younger than 4 years of age, n=175; pharmacokinetic and tolerability study, n=65; and two 1 year open label follow on safety studies, n=54 and n=431) was similar to that observed in the adult studies of patients with epilepsy. The most common adverse events observed in the 12-week study with pregabalin treatment were somnolence, pyrexia, upper respiratory tract infection, increased appetite, weight increased, and nasopharyngitis. The most common adverse events observed in the 14-day study with pregabalin treatment were somnolence, upper respiratory tract infection, and pyrexia.

Cross-check medications

Review your medication to ensure that there are no potentially harmful drug interactions or contraindications.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈